Larvol Delta - Avenge-Bio-Receives-FDA-Fast-Track-Designation-for-AVB001-a-Novel-Cell-Therapy-Leveraging-the-LOCOcyte-Immunotherapy-Platform

AVB-001 - Avenge Bio

https://www.prnewswire.com/news-releases/avenge-bio-receives-fda-fast-track-designation-for-avb-001-a-novel-cell-therapy-leveraging-the-lococyte-immunotherapy-platform-301943619.html

Oct 2, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next